Back to results
US 8,481,023 B2Granted
Oncolytic rhabdovirus
AssigneeOttawa Hospital Research Institute
InventorsDavid Stojdl, Christopher Brown, John Bell
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
Claims4
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated oncolytic rhabdovirus encoding an M or G protein having an amino acid sequence at least 85% identical to SEQ ID NO:5 or SEQ ID NO:4.
Dependencies are inferred from the claim text.